How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?

@article{Kerola2012HowEI,
  title={How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?},
  author={A. Kerola and M. Kauppi and T. Kerola and T. Nieminen},
  journal={Annals of the Rheumatic Diseases},
  year={2012},
  volume={71},
  pages={1606 - 1615}
}
Rheumatoid arthritis (RA) is a chronic inflammatory disease which is associated with an increased cardiovascular (CV) burden. Whether the risk is already present at the time of RA diagnosis remains a key area of debate. The aim of this review was to evaluate the existence of both subclinical CV changes, including endothelial dysfunction and atherosclerosis, CV risk factors, as well as CV disease manifestations such as coronary heart disease, myocardial infarction, congestive heart failure and… Expand
The Characteristics of Chronic Heart Failure in Rheumatoid Arthritis
TLDR
The findings emphasize the role and need of further larger studies in this field, which will bring to early identification and treatment of RA-subjects with HF and a decrease in mortality rates. Expand
The evolution of early arthritis and cardiovascular risk
TLDR
There are many risk factors of varying strength for the development of rheumatoid arthritis, and a possible new definition of remission, with more patient-reported outcomes, could be the normality scale. Expand
Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis.
TLDR
The results indicated that the appropriate management of RA may have affected the inflammatory status of these patients and consequently may have impacted upon subclinical atherosclerosis. Expand
Addressing cardiovascular risk factors and therapy effects in rheumatoid arthritis: implications for atherosclerosis and cardiovascular disease
TLDR
Results suggest that apolipoproteins and anti-PC antibodies may have independent roles in subclinical atherosclerosis in patients with RA and the relationships of inflammatory and novel biomarkers with incident CVD morbidity and all-cause mortality are examined. Expand
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion
TLDR
Issues regarding cardiovascular risk in rheumatoid arthritis and its management will be addressed, according to evidence presented in the latest studies and the own experience-based opinion. Expand
The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis
TLDR
The relationship between the improvement in disease activity and heart rate is remarkable because this could imply a 10-year CV mortality risk difference of 24%. Expand
Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review
TLDR
The burden of CVD in RA and associated traditional CV risk factors are highlighted, including the complexity of dyslipidemia inRA and the so-called ‘lipid paradox’. Expand
Cardiovascular risk in rheumatoid arthritis.
TLDR
There is some evidence that the cardiovascular risk increase associated with nonsteroidal anti-inflammatory drug therapy may be smaller in RA patients than in the general population, and the management of dyslipidemia remains suboptimal. Expand
Cardiovascular risk factors in patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs.
TLDR
The burden of CVD in RA and associated traditional CV risk factors are highlighted, including the complexity of dyslipidemia inRA and the so-called ‘lipid paradox’. Expand
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
TLDR
Autoantibodies appear to increase CVD risk in rheumatoid arthritis, however, the magnitude of the increase and the types of CVD outcomes affected are still unclear. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation
TLDR
To investigate the presence of subclinical atherosclerosis in the early stages of RA, the cIMT and plaque were measured using carotid duplex scanning in 40 RA patients with disease duration < 12 months and in 40 control subjects matched for age, sex and established cardiovascular risk factors. Expand
How early is the atherosclerotic risk in rheumatoid arthritis?
TLDR
A multidisciplinary cardiovascular risk management is required to provide the better care of patients with RA at disease onset and that particular immune and inflammatory factors, predating disease presentation, may be associated with increased risk of accelerated atherosclerosis in patients with early disease. Expand
Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
TLDR
This review of the literature is to summarize aspects of vascular alterations found in the cardiovascular system of RA patients and to relate them to the clinically relevant cardiovascular morbidity and mortality and evaluate what these abnormalities and complications might in the end imply for clinical management. Expand
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness
TLDR
In patients with early RA, IMT and ED-FMD were, to a greater extent than in controls, related to biomarkers known to be associated with endothelial dysfunction and atherosclerosis, and in patients with newly diagnosed RA, they were related to traditional CVD risk factors. Expand
Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.
TLDR
It is shown that DMARDs, beyond the well known antiphlogistic effects, are able to improve coronary microcirculation without a direct effect on IMT and ADMA, clinical markers of atherosclerosis. Expand
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
TLDR
The atherogenic lipid profile and subclinical atherosclerosis are features of early RA, which improved after therapy, and early intervention and control of the disease activity may reduce the risk of Atherosclerosis and cardiovascular events in patients with RA. Expand
Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity
TLDR
Skin microvascular function is preserved in early, DMARD-naive RA patients with moderately active RA but low systemic inflammatory activity, and both the extent of the systemic inflammation and disease duration may be important determinants of microv vascular dysfunction and subsequent increased risk for cardiovascular disease. Expand
Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease
TLDR
In patients with RA without CV disease, endothelial dysfunction and carotid IMT increased with the duration of RA, and the association between FMD and carotin IMT values was observed only in patients with long disease duration. Expand
Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study
TLDR
The occurrence of new CV events in very early RA was explained by traditional CV risk factors and was potentiated by high disease activity, which may have implications for cardio-protective strategies in RA. Expand
The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
TLDR
Compared with persons without RA, patients with RA have twice the risk of developing congestive heart failure and this excess risk is not explained by traditional CV risk factors and/or clinical ischemic heart disease. Expand
...
1
2
3
4
5
...